Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00082537
Status:
COMPLETED
Last Update Posted:
2017-02-23
First Post:
2004-05-11
Brief Title:
MK0991 Versus Amphotericin B for Empirical Therapy in Febrile Neutropenic Pediatric Patients 0991-044
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Multicenter Double-Blind Randomized Comparative Study to Evaluate the Safety Tolerability and Efficacy of Caspofungin Versus Amphotericin B Liposome for Injection as Empirical Therapy in Pediatric Patients With Persistent Fever and Neutropenia
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a double-blind randomized study of MK0991 versus liposomal amphotericin B in the empirical treatment of pediatric patients ages 2 through 17 years who have an absolute neutrophil count ANC below 500microliter and who have fever despite broad antibiotic coverage Such patients would be candidates for empirical therapy with an intravenous anti-fungal agent
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004_101 | None | None | None |
| Formerly-0404ETPP | None | None | None |
| MK0991-044 | None | None | None |